CD276, first identified in 2001 as a member of the B7 ligand family [26], is expressed by antigen-presenting cells, macrophages, and tumor cells, and has inhibitory effects on T-cells; these effects allow tumor cells to evade immune responses [25,27]. Here, CD276 is linked to neoplasm.